H.R. 7188 · 118th Congress · Health
Shandra Eisenga Human Cell and Tissue Product Safety Act
- IntroducedFeb 1, 2024 Done
- CommitteeReported Nov 22, 2024 Done
- House floorPassed by voice vote · Dec 16, 2024 Done
- Senate floorDied Jan 3, 2025 Stopped here
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.
Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments.
The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.
Congressional Research Service · summary of “Reported to House” version · Nov 22, 2024
Who lobbies on it
No lobbying filing on file names H.R. 7188.
Organizations that named H.R. 7188 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
16 actions · newest first- Dec 17, 2024Received in the Senate.
- Dec 16, 2024Motion to reconsider laid on the table Agreed to without objection.
- Dec 16, 2024On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
- Dec 16, 2024Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Show all 16 actionsShow fewer
- Dec 16, 2024DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
- Dec 16, 2024Considered under suspension of the rules. (consideration: CR H7167-7170)
- Dec 16, 2024Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
- Nov 22, 2024Placed on the Union Calendar, Calendar No. 632.
- Nov 22, 2024Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
- Sep 18, 2024Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
- Sep 18, 2024Committee Consideration and Mark-up Session Held
- May 16, 2024Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
- May 16, 2024Subcommittee Consideration and Mark-up Session Held
- Feb 2, 2024Referred to the Subcommittee on Health.
- Feb 1, 2024Referred to the House Committee on Energy and Commerce.
- Feb 1, 2024Introduced in House